First reported case in Canada of anaphylaxis to lupine in a child with peanut allergy

Allergy, Asthma & Clinical Immunology



•  Case report
• Open Access

• Lianne Soller,
• Sebastien La Vieille and
• Edmond S. Chan

Allergy, Asthma & Clinical Immunology201814:64

https://doi.org/10.1186/s13223-018-0303-4

Abstract

Background

Lupine is a member of the legume family and is often used in many food products in Europe (e.g. pasta, pizza, sauces, etc.) as a wheat or soy substitute. Lupine cross-reacts with peanut, and cases of allergic reactions to lupine in peanut-allergic patients have been reported in Europe mainly. In contrast, lupine as an ingredient in food products is relatively new to the Canadian market.

The law of food allergy and accommodation in Canadian schools

Allergy, Asthma & Clinical Immunology


• Review
• Open Access

• Blake Murdoch,
• Eric M. Adams and
• Timothy CaulfieldEmail author

Allergy, Asthma & Clinical Immunology201814:67

https://doi.org/10.1186/s13223-018-0273-6

Abstract

Background

There is ongoing controversy surrounding the appropriate standards and limits of accommodation of children with food allergies in schools. We identify and explain how relevant Canadian common law, legislation, constitutional law and human rights policy can inform future school policy around allergy, disability and food bans.

Early IL-10 producing B-cells and coinciding Th/Tr17 shifts during three year grass-pollen AIT

October 2018Volume 36, Pages 475–488

Ulrich M. Zissler1

, 

Constanze A. Jakwerth1

, 

Ferdinand M. Guerth

, 

Lisa Pechtold

, 

Juan Antonio Aguilar-Pimentel

, 

Katharina Dietz

, 

Kathrin Suttner

, 

Guido Piontek

, 

Bernhard Haller

, 

Zuzana Hajdu

, 

Matthias Schiemann

, 

Carsten B. Schmidt-Weber

, 

Adam M. ChakerCorrespondence information about the author Adam M. ChakerEmail the author Adam M. Chaker

Open Access

PlumX Metrics

DOI: https://doi.org/10.1016/j.ebiom.2018.09.016

 |

Article Info

• Abstract

• Full Text
• Images
• References
• Supplemental Materials

• Graphical abstract

Abstract

Background

Allergen-specific immunotherapy (AIT) is a causative treatment in allergic airway disease, comprising long-term allergen administration and requiring three years of treatment. Mechanisms and biomarkers that translate into clinical efficacy remain urgently needed.

The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine H1 receptor

European Journal of Pharmacology

Volume 838, 5 November 2018, Pages 107-111

Full length article

Author links open overlay panelReggieBosmaaJellevan den BoraHenry F.VischeraLuisLabeagabRobLeursa

https://doi.org/10.1016/j.ejphar.2018.09.011

open access

Abstract

Drug-target binding kinetics has recently attracted considerable interest in view of the potential predictive power for in vivo drug efficacy. The recently introduced antihistamine bilastine has a long duration of in vivo drug action, which outlasts pharmacological active bilastine concentrations in blood. To provide a molecular basis for the long duration of action, we explored the kinetics of bilastine binding to the human histamine H1 receptor using [3H]mepyramine binding studies and compared its pharmacodynamics properties to the reference compounds fexofenadine and diphenhydramine, which have a long (60 ± 20 min) and short (0.41 ± 0.1 min) residence time, respectively. Bilastine shows a long drug-target residence time at the H1 receptor (73 ± 5 min) and this results in a prolonged H1 receptor antagonism in vitro (Ca2+ mobilization in Fluo-4 loaded HeLa cells), following a washout of unbound antagonist. Hence, the long residence time of bilastine can explain the observed long duration of drug action in vivo.

Article PDF

Oral immunotherapy with the ingestion of house dust mite extract in a murine model of allergic asthma

• Research
• Open Access

• Yao-Tung Wang†,
• Hsu-Chung Liu†,
• Hui-Chen Chen,
• Yen-Ching Lee,
• Tung-Chou Tsai,
• Hsiao-Ling Chen,
• Hueng-Chuen FanEmail author and
• Chuan-Mu ChenEmail author

†Contributed equally

Allergy, Asthma & Clinical Immunology201814:43

https://doi.org/10.1186/s13223-018-0269-2

Abstract

Background

Allergen-specific immunotherapy (ASIT) has the potential to modify allergic diseases, and it is also considered a potential therapy for allergic asthma. House dust mite (HDM) allergens, a common source of airborne allergen in human diseases, have been developed as an immunotherapy for patients with allergic asthma via the subcutaneous and sublingual routes. Oral immunotherapy with repeated allergen ingestion is emerging as another potential modality of ASIT. The aim of this study was to evaluate the therapeutic efficacy of the oral ingestion of HDM extracts in a murine model of allergic asthma.

Staphylococcus aureus from patients with chronic rhinosinusitis show minimal genetic association between polyp and non-polyp phenotypes

• Research article
• Open Access
• Open Peer Review
• 
  

• • 
    
• • 
    
  Jake Jervis BardyEmail author,
• Derek S Sarovich,
• Erin P Price,
• Eike Steinig,
• Steven Tong,
• Amanda Drilling,
• Judy Ou,
• Sarah Vreugde,
• Peter-John Wormald and
• Alkis J Psaltis

BMC Ear, Nose and Throat Disorders201818:16

https://doi.org/10.1186/s12901-018-0064-1

Open Peer Review reports

Abstract

Background

Staphylococcus aureus has a high prevalence in chronic rhinosinusitis (CRS) patients and is suggested to play a more etiopathogenic role in CRS patients with nasal polyps (CRSwNP), a severe form of the CRS spectrum with poorer surgical outcomes. We performed a microbial genome-wide association study (mGWAS) to investigate whether S. aureus isolates from CRS patients have particular genetic markers associated with CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP).

Highlights of eosinophilic chronic rhinosinusitis with nasal polypsin definition, prognosis, and advancement

REVIEW ARTICLE 

Open Access

Hongfei Lou MD, PhD 

 

Nan Zhang MD, PhD 

 

Claus Bachert MD, PhD 

 

Luo Zhang MD, PhD

https://doi.org/10.1002/alr.22214

Abstract

Background

Tissue eosinophils are characteristic of inflammation in most but not all patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and may be useful for defining subgroups and making treatment choices. However, no consistent diagnostic criteria for CRSwNP with eosinophilic inflammation have been established.

Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients

Eur Rev Med Pharmacol Sci 2018; 22 (3): 820-828

DOI: 10.26355/eurrev_201802_14318

A. Demonte, M.B. Guanti, S. Liberati, A. Biffi, F. Fernando, M. Fainello, P. Pepe

Department of Surgical, Medical, Dental and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine; Dermatology Unit; University of Modena and Reggio Emilia, Modena, Italy. patrizia.pepe@unimore.it

---

• PHARMACOLOGY

OBJECTIVE: Bilastine is a highly selective, non-sedating antihistamine, indicated for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria. Available data suggest that bilastine interferes neither with driving ability nor with flying-related performance. However, no data are available on the effect of bilastine on the driving ability in extreme conditions. Here we analyzed the effect of 7 days treatment with 20 mg bilastine in patients with allergic rhinitis and/or chronic urticaria, on psychophysical performance assessed by the Formula One (F1) high-speed simulator-driving test.